Trials / NCT06455826
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Completed Phase 1 Drug / neuroprotection
- Sponsor
- PYC Therapeutics
- Treatment
- VP-001
- Gene
- PRPF31
- Conditions
- Retinitis Pigmentosa 11, Retinal Degeneration, Eye Diseases, Retinal Disease, Retinal Dystrophies
- Ages
- 12 Years to no upper limit
- Enrollment
- 6 participants
- Started
- 2024-06-13
- Main results expected
- 2025-09-24
- Results posted
- Not yet
- Record last updated
- 2026-05-29
What the study is testing
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Where it runs
United States (5)
- University of Florida Health, Jacksonville, Florida
- University of Michigan Kellogg Eye Center, Ann Arbor, Michigan
- Oregon Health and Science University - Casey Eye Institute, Portland, Oregon
- Retina Foundation of the Southwest, Dallas, Texas
- Baylor College of Medicine- Alkek Eye Center, Houston, Texas